Bambusa Therapeutics, Inc. (NASDAQ:BBTX – Get Free Report) Director Helmut Wolfgang Jeggle acquired 375,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was purchased at an average cost of $16.00 per share, with a total value of $6,000,000.00. Following the purchase, the director owned 9,264,301 shares of the company’s stock, valued at $148,228,816. The trade was a 4.22% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Bambusa Therapeutics Trading Up 6.7%
Shares of NASDAQ BBTX traded up $1.01 during midday trading on Monday, hitting $16.00. The company’s stock had a trading volume of 433,191 shares. Bambusa Therapeutics, Inc. has a 12-month low of $13.60 and a 12-month high of $16.06.
Recommended Stories
- Five stocks we like better than Bambusa Therapeutics
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Bambusa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bambusa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
